Narrowing a drug's clinical claims is the ultimate escape hatch for applications doomed by trial design disputes.
When contentious statistical disagreements or negative advisory votes threaten to kill a drug's regulatory review, developers can salvage the application by stripping out disputed endpoints and refining the proposed indication.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Faced with a negative advisory panel vote on its primary endpoint, the developer salvaged its application by narrowing its focus to a different functional endpoint.
Capricor refined and narrowed its proposed therapeutic indication to salvage its drug application following negative advisory feedback.
Faced with trial design disputes, Capricor salvaged its regulatory application by abandoning the contested cardiac indication to focus on a narrower, statistically validated skeletal muscle claim.
Capricor amended its BLA to target a narrower upper-limb skeletal muscle claim rather than risk an outright rejection of its heart-focused data.
To salvage its BLA after an adverse advisory committee vote, Capricor narrowed its proposed indication to the preservation of upper limb function.
Capricor submitted a major amendment to narrow its drug's proposed clinical use to save the application from a complete rejection.
With the lesion-count primary dead at P=.0986, the application survived by anchoring on the ranked secondary imaging endpoint — endpoint flexibility salvaging a review whose headline measure failed.